title: SYK regulates mTOR signaling in AML.
abstract: Spleen tyrosine kinase (SYK) was recently identified as a new target in acute myeloid leukemia (AML); however, its mechanistic role in this disease is poorly understood. Based on the known interaction between SYK and mammalian target of rapamycin (mTOR) signaling in lymphoma, we hypothesized that SYK may regulate mTOR signaling in AML. Both small-molecule inhibition of SYK and SYK-directed shRNA suppressed mTOR and its downstream signaling effectors, as well as its upstream activator, AKT. Moreover, the inhibition of multiple nodes of the phosphatidylinositol 3'-kinase (PI3K) signaling pathway enhanced the effects of SYK suppression on AML cell viability and differentiation. Evaluation of the collateral mitogen-activated protein kinase (MAPK) pathway revealed a heterogeneous response to SYK inhibition in AML with downregulation of MEK and extracellular signal-regulated kinase (ERK) phosphorylation in some AML cell lines but a paradoxical increase in MEK/ERK phosphorylation in RAS-mutated AML. These studies reveal SYK as a regulator of mTOR and MAPK signaling in AML and demonstrate that inhibition of PI3K pathway activity enhances the effects of SYK inhibition on AML cell viability and differentiation.
authors.affiliation: Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Carnevale
authors.forename: L
authors.initials: L
authors.lastname: Ross
authors.forename: A
authors.initials: A
authors.lastname: Puissant
authors.forename: V
authors.initials: V
authors.lastname: Banerji
authors.forename: R M
authors.initials: RM
authors.lastname: Stone
authors.forename: D J
authors.initials: DJ
authors.lastname: DeAngelo
authors.forename: K N
authors.initials: KN
authors.lastname: Ross
authors.forename: K
authors.initials: K
authors.lastname: Stegmaier
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000235:genetics / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D000072377:Syk Kinase; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D048049:Extracellular Signal-Regulated MAP Kinases; D047908:Intracellular Signaling Peptides and Proteins; D020928:Mitogen-Activated Protein Kinases; D019869:Phosphatidylinositol 3-Kinases; D011505:Protein-Tyrosine Kinases; D051057:Proto-Oncogene Proteins c-akt; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D000072377:Syk Kinase; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human; C000606896:SYK protein, human
references.citation: J Immunol. 2007 Jan 1;178(1):111-21
references.pmid: 17182546
references.citation: Exp Hematol. 2010 Aug;38(8):666-76
references.pmid: 20382200
references.citation: Leukemia. 2013 Jul;27(7):1479-86
references.pmid: 23321953
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008
references.pmid: 16946104
references.citation: Cell. 2006 Mar 24;124(6):1283-98
references.pmid: 16564017
references.citation: Leukemia. 2008 Dec;22(12):2159-68
references.pmid: 18784743
references.citation: Clin Cancer Res. 2009 Nov 1;15(21):6732-9
references.pmid: 19843663
references.citation: Cell. 2007 Jan 26;128(2):257-67
references.pmid: 17254965
references.citation: Blood. 2008 Sep 15;112(6):2305-17
references.pmid: 18621930
references.citation: Nature. 1995 Nov 16;378(6554):303-6
references.pmid: 7477353
references.citation: Blood. 2006 Dec 15;108(13):4202-4
references.pmid: 16946300
references.citation: Mol Cell Biol. 2005 Apr;25(7):2558-72
references.pmid: 15767663
references.citation: Leukemia. 1997 Sep;11(9):1469-77
references.pmid: 9305600
references.citation: Clin Cancer Res. 2010 Nov 15;16(22):5424-35
references.pmid: 20884625
references.citation: Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9
references.pmid: 8643484
references.citation: Adv Cancer Res. 1981;35:269-335
references.pmid: 7041539
references.citation: Clin Cancer Res. 2011 Jul 1;17(13):4378-88
references.pmid: 21415215
references.citation: Leukemia. 2012 Apr;26(4):795-805
references.pmid: 21926965
references.citation: Blood. 2005 Mar 15;105(6):2527-34
references.pmid: 15550488
references.citation: Blood. 2008 Feb 15;111(4):2230-7
references.pmid: 18006696
references.citation: J Clin Invest. 2008 Sep;118(9):3065-74
references.pmid: 18725988
references.citation: Leukemia. 2004 Mar;18(3):548-55
references.pmid: 14749700
references.citation: Genome Biol. 2006;7(7):R61
references.pmid: 16859521
references.citation: Br J Haematol. 1992 Jul;81(3):370-3
references.pmid: 1390209
references.citation: Leukemia. 2012 Jun;26(6):1195-202
references.pmid: 22143671
references.citation: J Med Chem. 2008 Sep 25;51(18):5522-32
references.pmid: 18754654
references.citation: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7977-82
references.pmid: 12799470
references.citation: Cell. 1983 Jul;33(3):749-57
references.pmid: 6683594
references.citation: Blood. 2005 Dec 15;106(13):4261-8
references.pmid: 16150937
references.citation: Blood. 2009 Apr 30;113(18):4179-87
references.pmid: 19008455
references.citation: Mol Cell Biol. 1999 Mar;19(3):1871-80
references.pmid: 10022874
references.citation: Mol Cell Biol. 2003 Dec;23(24):8992-9002
references.pmid: 14645512
references.citation: Blood. 2005 Oct 15;106(8):2841-8
references.pmid: 15998836
references.citation: Immunology. 2009 Sep;128(1 Suppl):e376-84
references.pmid: 19175792
references.citation: Mol Cancer Res. 2007 Jan;5(1):95-108
references.pmid: 17259349
references.citation: Cell. 2009 May 29;137(5):821-34
references.pmid: 19490892
references.citation: Leukemia. 2010 Oct;24(10):1686-99
references.pmid: 20703258
references.citation: J Exp Med. 2010 May 10;207(5):1031-44
references.pmid: 20439541
references.citation: Nature. 2010 Mar 18;464(7287):427-30
references.pmid: 20179705
references.citation: Int J Cancer. 2009 Oct 1;125(7):1710-20
references.pmid: 19507250
references.citation: FASEB J. 2007 Apr;21(4):1075-87
references.pmid: 17242159
references.citation: Blood. 2009 Aug 20;114(8):1618-27
references.pmid: 19458359
references.citation: Clin Cancer Res. 2012 Mar 15;18(6):1716-25
references.pmid: 22167413
references.citation: J Exp Med. 2006 Dec 25;203(13):2829-40
references.pmid: 17130299
references.citation: J Biol Chem. 2007 May 11;282(19):14056-64
references.pmid: 17360704
references.citation: Blood. 1990 Nov 1;76(9):1704-9
references.pmid: 2224119
references.citation: Blood. 2006 Dec 15;108(13):4156-62
references.pmid: 16912221
references.citation: Nat Genet. 2004 Mar;36(3):257-63
references.pmid: 14770183
references.citation: Blood. 2009 Mar 12;113(11):2508-16
references.pmid: 18981293
references.citation: J Biol Chem. 2008 Mar 28;283(13):8601-10
references.pmid: 18223253
references.citation: Blood. 2008 Feb 15;111(4):2269-79
references.pmid: 18056483
references.citation: Blood. 2001 Feb 15;97(4):1050-5
references.pmid: 11159536
references.citation: Genes Dev. 2003 Aug 1;17(15):1841-54
references.pmid: 12869584
references.citation: Cancer Cell. 2009 Oct 6;16(4):281-94
references.pmid: 19800574
references.citation: Br J Haematol. 2012 Jan;156(2):205-12
references.pmid: 22082314
references.citation: J Immunol. 1999 Mar 15;162(6):3491-7
references.pmid: 10092805
references.citation: Leukemia. 2007 May;21(5):1005-14
references.pmid: 17330105
references.citation: Nat Rev Mol Cell Biol. 2009 May;10(5):307-18
references.pmid: 19339977
references.citation: J Biol Chem. 2009 Mar 20;284(12):8023-32
references.pmid: 19150980
references.citation: Blood. 2012 Sep 27;120(13):2679-89
references.pmid: 22826565
references.citation: Leukemia. 2006 Feb;20(2):313-8
references.pmid: 16341044
references.citation: Br J Haematol. 2006 Feb;132(3):303-16
references.pmid: 16409295
references.citation: Genes Chromosomes Cancer. 2000 Dec;29(4):333-8
references.pmid: 11066077
references.citation: Blood. 2010 Apr 1;115(13):2578-85
references.pmid: 19965662